Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma

NCT00409214 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma

Interventions

DRUG: LS11 (talaporfin sodium)
DEVICE: Light source (interstitial light emitting diodes)
PROCEDURE: Intraoperative placement of device in glioma

Sponsor

Light Sciences Oncology